Partly based on University of Bern research, Synendos aims to restore the endocannabinoid system to treat dysfunction in the central nervous system.

The healthcare navigation software provider closed a $37.5m round co-led by Cigna Ventures and Humana and backed by Optum Ventures.

Sinopharm Capital and the WuXi AppTec-backed 6 Dimensions Capital are among the investors in the inflammatory and autoimmune disease drug developer.

The round included Jubilant Biosys, an existing investor in the liver disease drug startup as well as its contract research organisation partner.

Allana Group has returned to back a $17.6m round for the dispensary chain owner, five years after its contribution to a $3.2m round for the company.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Neuros Medical, a Case Western Reserve University spinout, has raised $69.8m since it was founded in 2008.

The cancer immunothrapy developer has filed to raise up to $100m in an offering that will follow $211m from backers including Celgene and Bristol-Myers Squibb.

Boston Scientific-backed pain relief implant developer Neuros has now raised about $70m in total and is targeting $42.8m in its latest round.

Adagio has raised money in a GV-led series B round that will support the entry of its covid-19 drug candidate into clinical trials early next year.